Correction of Top 20 Shareholders in Annual Report 2018
Total Page:16
File Type:pdf, Size:1020Kb
CORRECTION – ANNUAL REPORT TO SHAREHOLDERS Adelaide, Australia, 4 October 2018: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company) refers to its announcement made on 27 September 2018 released under the title “Annual Report to Shareholders”. Please note that the Top 20 Shareholders table on page 60 of the Annual Report contained errors which have now been corrected. An updated Annual Report is attached. All other sections of the Annual Report remain unchanged. – ENDS – About LBT Innovations LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company’s second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT’s 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT’s intelligent imaging and machine learning software, and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. CONTACTS LBT Innovations Investor Enquiries Media Relations Brent Barnes David Allen / John Granger Sarah Kemter Chief Executive Officer & Managing Director Hawkesbury Partners Monsoon Communications Tel: +61 8 8227 1555 Tel: +61 2 9103 9494 Tel: +61 3 9620 3333 E: [email protected] E: [email protected] E: [email protected] Page 1 of 1 Annual Report For the year ended 30 June 2018 Advancing. Expanding. Commercialising. LBT Innovations ABN 95 107 670 673 Principal Place of Business & Registered Office Level 8, 44 Waymouth Street Adelaide SA 5000 Phone: +61 8 8227 1555 Website: lbtinnovations.com Directors Catherine Mary Costello (Commenced chair position 1 August 2017) Chairman (Formerly non-executive director) Robert Andrew Finder (Retired 31 July 2017) Chairman Brenton Barnes Chief Executive Officer and Managing Director Stephen Paul Mathwin Non-Executive Director Caroline Popper Non-Executive Director Dr Glenn Haifer (Commenced 1 September 2017) Non-Executive Director Matthew Michalewicz (Commenced 1 September 2017) Non-Executive Director Company Secretary Daniel Hill Company Secretary (Formerly Company Secretary and Chief Financial Officer) Retired as Chief Financial Officer on 24 August 2017 Chief Financial Officer Raymond Ridge (Commenced 25 August 2017) Lawyers Thomson Geer Lawyers 19 Gouger Street Adelaide SA 5000 Auditors HLB Mann Judd Audit (SA) Pty Ltd 167-169 Fullarton Rd Dulwich SA 5065 Share Register Computershare Investor Services Pty Limited GPO Box 1903 Adelaide SA 5001 Listed Securities LBT: Ordinary Shares Contents Chairman’s Letter to Shareholders .....................................5 Directors’ Report ................................................................ 6-23 Auditors’ Independence Declaration............................... 24 Statement of Comprehensive Income ............................ 25 Statement of Financial Position ......................................... 26 Statement of Changes in Equity .........................................27 Statement of Cash Flows ..................................................... 28 Notes to the Financial Statements ............................. 29-53 Directors’ Declaration ..........................................................54 Independent Auditor’s Report .................................... 55-58 Shareholder Information............................................... 59-61 APAS® Independence The first automated culture plate reader. The APAS Independence is an innovative in vitro diagnostic instrument for automated imaging, analysis and interpretation of agar culture plates. 1st sale completed to St. Vincent’s Hospital 3x faster Melbourne. 10,000 than manual reading providing cost and patient clinical study efficiency gains. grants clearance from FDA. Fast Accurate Cost Accelerated effective results Commercial launch Total global market opportunity estimated at 13,000 laboratories Establishing early presence US soft launch early 2019. Establishing early presence First placement in Labor Wisplinghoff (largest lab in Germany). EU centre of excellence and on the ground technical support. Launch market Local and leading technology and microbiology knowledge. Establish training and sales tools which are modelled, tested and ready for Targeting expansion into larger markets. medium to large laboratories Proprietary patented Upfront and annual fees Expanding leadership technology providing an attractive team and board revenue model 2017–2018 highlights and commercial achievements August 2017 Board rejuvenation November 2017 St Vincent’s Melbourne completes clinical validation December 2017 Sale of MicroStreak IP to AutoBio and $2m placement March 2018 AU sales commence sales executive appointed February 2018 South Australian Government $4m low interest funding April 2018 Data presented at ECCMID largest global meeting April 2018 $7.9m Placement and Share Purchase Plan May 2018 APAS Independence placed in first EU site – Labor Dr Wisplinghoff May 2018 Strategic investor Planet Innovation invests in placement August 2018 First APAS Independence commercial sale; additional evaluations ongoing Chairman’s Letter Chairman’s Letter to Shareholders On behalf of the LBT Innovations board, I am excited about the year ahead and I am I’m pleased to present the company’s confident about the ability of our management 2017-2018 annual report after a year team to achieve the operational and strategic objectives set by the board. in which we made great strides in advancing and commercialising On behalf of the board, I would like to thank the team at LBT Innovations and our joint our technology. This culminated venture partner Hettich Holding Beteiligungs- in the August 2018 sale of our first und Verwaltungs-GmbH for their unrelenting APAS Independence instrument to contributions over the past year. I would also like Melbourne’s St Vincent’s Hospital. to thank my fellow board members and our CEO, Brent Barnes. Since the beginnings of LBT, the company has I would also like to extend my appreciation to all focused on inventing innovative technology of our shareholders for their continued support of that addresses unmet needs for clinical LBT. We were especially pleased with the support microbiologists. We are very proud of of the existing shareholders - plus new investors our competencies in navigating complex - when we raised $7.9 million early this year. This engineering development and regulatory funding runway allows us to plan and execute on processes, thus delivering instrumentation our sales strategies for APAS Independence. that enhances efficiencies in busy pathology laboratories globally. We are confident APAS Independence will dramatically improve the way clinical Our core passions are finding efficiencies and microbiology laboratories process specimens. developing medical technology and we continue to be proactive in establishing new ideas for our As the company looks to establish a current ventures and future endeavours. global footprint, we are realistic enough to understand that new technology takes Globally, qualified clinical microbiologists are in time. Still, I look forward to seeing more short supply. Recently published data indicates laboratories being positively impacted by our the US vacancy rate at any one time is 9%, while instrument as we continue our early global the average age of an Australian microbiologist commercialisation efforts. is 51. Sincerely, With an estimated 28,000 clinical microbiology laboratories globally processing millions of agar plates per day, there is a clear need for automation of this process. Over the past decade, artificial intelligence (AI) has been placed into workplaces in almost every industry worldwide. Our APAS technology is Catherine Costello the only AI technology for clinical microbiology Chairman cleared by the US Food & Drug Administration. In November 2017, we successfully completed an independent evaluation of our APAS Independence instrument at St Vincent’s Hospital in Melbourne. This appraisal was the first installation of the instrument globally and resulted in the first sale in August 2018. We also have a number of ongoing initiatives and collaboration efforts in place with laboratories, universities and the South Australian Government to supplement the work of our highly skilled workforce. These partnerships provide the necessary platform for LBT to be able to collaborate and organically grow. 5 Annual Report 2018 Director’s Report Your directors present their report on the Company for the year ended 30 June 2018. Directors Company Secretary The names of the directors in office at any time (Retired as Chief Financial Officer on 24 August during or since the end of the year are: 2017, remains Company Secretary) Catherine Mary Costello The following person held the position (Commenced chair position 1 August 2017) of Company Secretary at the end of the Chairman (Formerly non-executive director) financial year: Robert Andrew Finder Daniel Hill (Retired 31 July 2017) Qualifications Chairman Bachelor of Accountancy, Chartered Accountant, Brenton Barnes MBA, Master of Applied Finance, Certificate in Governance Practice. Chief Executive Officer and Managing Director